Results 221 to 230 of about 2,612,022 (237)

Botulinum toxin type A for treatment of hyperhidrosis [PDF]

Therapy, 2005
Hyperhidrosis is defined as excessive sweating beyond that required to return the body temperature to normal. Focal hyperhidrosis commonly affects the axillae, palms, soles or face and often has a tremendous psychosocial and occupational impact on affected patients.
openaire   +1 more source

Some of the next articles are maybe not open access.

Related searches:

Botulinum toxin antibody type A titres after cessation of botulinum toxin therapy

Movement Disorders, 2002
AbstractIn some patients, therapy with botulinum toxin type A (BT‐A) becomes ineffective due to formation of antibodies (BT‐A‐AB). The time course of BT‐A‐AB titres after cessation of BT‐A therapy was quantitatively studied to determine whether and when they might drop.
Hans Bigalke, Dirk Dressler
openaire   +2 more sources

Botulinum toxin type A [PDF]

Inpharma Weekly, 1999
‘Poison can be employed as a means for destruction of life or as a treatment for the sick’. Such is the case with botulinum toxin type A, said Dr Roger Aoki from Allergan Inc., US, speaking at the 4th Congress of the European Federation of Neurological Societies [Lisbon, Portugal; September 1999].
openaire   +1 more source

Detoxification of Crystalline Botulinum Type A Toxin

The Journal of Immunology, 1947
Summary Botulinum Type A toxoid has been prepared from crystalline toxin by the addition of formaldehyde. The most active preparation consisted of one component electrophoretically, immunized mice in a dose containing 0.01γ of toxoidnitrogen and was 2400 times more active antigenically than crude toxoid on the basis of nitrogen-content.
G A, HOTTLE, A, ABRAMS
openaire   +2 more sources

Pharmacology and immunology of botulinum toxin type A

Clinics in Dermatology, 2003
The utility of botulinum neurotoxins as therapeutic and esthetic agents depends on their ability to inhibit neurotransmitter release from selected neurons, remain localized at the site of injection, and evade the body's immunologic defenses. The clinical correlates of these actions, respectively, are efficacy, safety, and a low rate of antibody ...
openaire   +3 more sources

Botulinum toxin type A for the treatment of migraine

Expert Opinion on Pharmacotherapy, 2006
Migraine is a common and debilitating disorder that often requires prophylactic therapy, particularly for those migraine patients who meet the diagnostic criteria for chronic daily headache (chronic migraine). Existing prophylactic treatments for migraine are inadequate for many patients due to their modest efficacy and/or systemic side effects ...
openaire   +3 more sources

Botulinum toxin type A in experimental neuropathic pain

Journal of Neural Transmission, 2005
A peripheral application of botulinum toxin type A (7 U/kg) has significantly reduced thermal and mechanical hypersensitivity in rats with the partial sciatic nerve transection as a classical model of surgical neuropathy.
Zdravko Lacković, Maja Relja, Lidija Bach-Rojecky   +2 more
openaire   +4 more sources

Observations on the Type A Toxin of Clostridium botulinum

Nature, 1951
THE recent communication by Wentzel, Sterne and Polson1 makes it desirable to record some supplementary observations made in the chemical investigation of a number of toxins, especially that produced by Clostridium botulinum Type A. In the present experiments, the toxicity was determined by intraperitoneal injection into white mice of 20 gm. weight.
openaire   +3 more sources

Botulinum Toxin Type A: Evaluation of Onset and Satisfaction

Plastic Surgical Nursing, 2018
With the increasing interest in nonsurgical cosmetic procedures, this research study sought to evaluate the onset of Botulinum toxin Type A (BoNTA) between naive and non-naive consumers and its effect on satisfaction. This single-blinded research study consisted of 15 adults with scheduled appointments for neurotoxin treatment of undesired glabellar ...
Gregory Alouf, Erin Alouf, Tina Murphy
openaire   +3 more sources

Botulinum toxin type A (BOTOX) for treatment of migraine

Seminars in Cutaneous Medicine and Surgery, 2001
An open-label study and 2 double-blind, placebo-controlled studies have provided supporting evidence of botulinum toxin type A (BTX-A) as an effective, well-tolerated treatment for migraine. Observed durations of benefit were consistent with known properties of BTX-A.
Mitchell F. Brin, Andrew Blitzer, Janice M. Pogoda, William J. Binder   +3 more
openaire   +5 more sources